Aura Biosciences, Inc.
AURA
$7.64
-$0.01-0.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 150.80% | 29.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.87% | 28.01% | |||
| Operating Income | -37.87% | -28.01% | |||
| Income Before Tax | -35.44% | -31.83% | |||
| Income Tax Expenses | 163.64% | -26.67% | |||
| Earnings from Continuing Operations | -35.48% | -31.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.48% | -31.79% | |||
| EBIT | -37.87% | -28.01% | |||
| EBITDA | -38.21% | -28.28% | |||
| EPS Basic | 3.66% | -31.11% | |||
| Normalized Basic EPS | 3.69% | -31.15% | |||
| EPS Diluted | 3.66% | -31.11% | |||
| Normalized Diluted EPS | 3.69% | -31.15% | |||
| Average Basic Shares Outstanding | 40.65% | 0.52% | |||
| Average Diluted Shares Outstanding | 40.65% | 0.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||